#NetizensVoice
American drug after 7 years of research patented by China’s WIV
2013--2016, U.S.A.
Gilead Sciences, Inc. obtained initial clinical trials data after testing the effectiveness of Remdesivir against the ebola virus.
2018--2019, U.S.A.
Upon further research into Remdesivir, Gilead found out that the drug was not too effective against the ebola virus.
26 January 2020, U.S.A.
After the first novel coronavirus patient in the U.S. was hospitalised for 5 days, American doctors used the drug on him. This was the first use of Remdesivir around the globe to treat the novel coronavirus. The result was surprisingly good.
21 January, Wuhan!!!
Wuhan Institute of Virology (WIV) of the Chinese Academy of Sciences applied for a Chinese invention patent on the use of Remdesivir against 2019-nCoV. Please keep in mind that Wuhan never conducted any trials on humans. Their data suggested only effectiveness on cells outside of human bodies.
Pharmaceutical experiments from cells outside human bodies to use on patients will take at least 5 to 10 years of clinical trials. They still need to study the side effects, detect toxicity, and compare the results through randomised double-blind experiments.
However, WIV still squatted the patent first. Ruthless. Source: WIV official website.
31 January, U.S.A.
The U.S. published the treatment of the first patient in America in academic journal. The result was encouraging. Stocks of the maker of Remdesivir soared.
2 February, U.S.A. & China
The Trump administration granted a special permission to exempt the patent of the drug, and published the molecular structure of the drug in an emergency. Before that, Gilead had long obtained a CEPI patent.
CEPI is a new organisation in the U.S. to expedite vaccine development and epidemic prevention, and has broad influences. Currently, in addition to Gilead, CEPI has two projects on hand that aim to develop anit-coronavirus drugs. One is a partnership with GlaxoSmithKline (GSK); another, with someone I know little off except that they started a new cellular engineering project on 14 February. In the meantime, our State Food and Drug Administration acted quickly and approved clinical trails on Remdesivir in China. There will be 270 patients taking part. Good news.
3 February, U.S.A. & China
Patients officially received treatments. Prof. Cao Bin’s team reported many good news indicating that the treatments had very good results, and even some news about nucleic acid test turning negative.
4 February, Wuhan Institute of Virology!!
A research paper by WIV on Remdesivir’s effectiveness against the novel coronavirus was published on Cell Research. On the day of the publication, WIV announced on their official web site that they already obtained the patent as early as 21 January. But they graciously announced, in order to resist the epidemic, that they would “temporarily waive the rights granted by the patent, and hope to do the least [they] can on the joint coordination with foreign pharmaceutical companies on epidemic prevention and control.”
Lastly, I don’t know what to say.
Good people never know how bad the bad people can be.
Bad people also never know how good the good people can be.
Wish you all in good health.
Screen cap as follows
Text-only Version
In compliance with international customs and for the sake of protecting national interest, we applied for Chinese invention patent (Use against 2019-nCoV) on 21 January, and will gain access to major countries of the world through the PCT (Patent Cooperation Agreement). If interested foreign enterprises wish to contribute to our effort of epidemic prevention and control, we can, upon mutual agreement subject to national needs, temporarily waive the rights granted by the patent, and hope to do the least we can on the joint coordination with foreign pharmaceutical companies on epidemic prevention and control.
Source: Ethan Tu Facebook, based on Weixin post now censored
https://bit.ly/2vazJIJ
https://bit.ly/31uXabA
#Remdesivir #Gilead #Patent #Coronavirus
American drug after 7 years of research patented by China’s WIV
2013--2016, U.S.A.
Gilead Sciences, Inc. obtained initial clinical trials data after testing the effectiveness of Remdesivir against the ebola virus.
2018--2019, U.S.A.
Upon further research into Remdesivir, Gilead found out that the drug was not too effective against the ebola virus.
26 January 2020, U.S.A.
After the first novel coronavirus patient in the U.S. was hospitalised for 5 days, American doctors used the drug on him. This was the first use of Remdesivir around the globe to treat the novel coronavirus. The result was surprisingly good.
21 January, Wuhan!!!
Wuhan Institute of Virology (WIV) of the Chinese Academy of Sciences applied for a Chinese invention patent on the use of Remdesivir against 2019-nCoV. Please keep in mind that Wuhan never conducted any trials on humans. Their data suggested only effectiveness on cells outside of human bodies.
Pharmaceutical experiments from cells outside human bodies to use on patients will take at least 5 to 10 years of clinical trials. They still need to study the side effects, detect toxicity, and compare the results through randomised double-blind experiments.
However, WIV still squatted the patent first. Ruthless. Source: WIV official website.
31 January, U.S.A.
The U.S. published the treatment of the first patient in America in academic journal. The result was encouraging. Stocks of the maker of Remdesivir soared.
2 February, U.S.A. & China
The Trump administration granted a special permission to exempt the patent of the drug, and published the molecular structure of the drug in an emergency. Before that, Gilead had long obtained a CEPI patent.
CEPI is a new organisation in the U.S. to expedite vaccine development and epidemic prevention, and has broad influences. Currently, in addition to Gilead, CEPI has two projects on hand that aim to develop anit-coronavirus drugs. One is a partnership with GlaxoSmithKline (GSK); another, with someone I know little off except that they started a new cellular engineering project on 14 February. In the meantime, our State Food and Drug Administration acted quickly and approved clinical trails on Remdesivir in China. There will be 270 patients taking part. Good news.
3 February, U.S.A. & China
Patients officially received treatments. Prof. Cao Bin’s team reported many good news indicating that the treatments had very good results, and even some news about nucleic acid test turning negative.
4 February, Wuhan Institute of Virology!!
A research paper by WIV on Remdesivir’s effectiveness against the novel coronavirus was published on Cell Research. On the day of the publication, WIV announced on their official web site that they already obtained the patent as early as 21 January. But they graciously announced, in order to resist the epidemic, that they would “temporarily waive the rights granted by the patent, and hope to do the least [they] can on the joint coordination with foreign pharmaceutical companies on epidemic prevention and control.”
Lastly, I don’t know what to say.
Good people never know how bad the bad people can be.
Bad people also never know how good the good people can be.
Wish you all in good health.
Screen cap as follows
Text-only Version
In compliance with international customs and for the sake of protecting national interest, we applied for Chinese invention patent (Use against 2019-nCoV) on 21 January, and will gain access to major countries of the world through the PCT (Patent Cooperation Agreement). If interested foreign enterprises wish to contribute to our effort of epidemic prevention and control, we can, upon mutual agreement subject to national needs, temporarily waive the rights granted by the patent, and hope to do the least we can on the joint coordination with foreign pharmaceutical companies on epidemic prevention and control.
Source: Ethan Tu Facebook, based on Weixin post now censored
https://bit.ly/2vazJIJ
https://bit.ly/31uXabA
#Remdesivir #Gilead #Patent #Coronavirus
UK tech company sues Huawei and Goodix for patent infringement
A small British technology company has accused Huawei and Goodix, China’s largest developer of smartphone fingerprint sensors, of infringing on its technology and has launched legal proceedings against both companies.
WaveTouch, a UK registered and owned company that was spun out of Technical University in Copenhagen, has filed claims against the two Chinese companies in the District Court of Düsseldorf, one of the main European patent courts.
WaveTouch alleges that a system that it designed to improve the accuracy of fingerprint readers underneath modern smartphone screens has been replicated by Goodix for a range of ultra-thin chips and used in millions of smartphones. It said Huawei has incorporated the disputed chip technology into a number of its smartphones including the P40 and the Mate 40.
Source: Financial Time #Feb25
https://www.ft.com/content/ce8b5a8e-214c-45c9-b972-6bdaf87fc0f9
#UK #Huawei #Goodix #Patent
A small British technology company has accused Huawei and Goodix, China’s largest developer of smartphone fingerprint sensors, of infringing on its technology and has launched legal proceedings against both companies.
WaveTouch, a UK registered and owned company that was spun out of Technical University in Copenhagen, has filed claims against the two Chinese companies in the District Court of Düsseldorf, one of the main European patent courts.
WaveTouch alleges that a system that it designed to improve the accuracy of fingerprint readers underneath modern smartphone screens has been replicated by Goodix for a range of ultra-thin chips and used in millions of smartphones. It said Huawei has incorporated the disputed chip technology into a number of its smartphones including the P40 and the Mate 40.
Source: Financial Time #Feb25
https://www.ft.com/content/ce8b5a8e-214c-45c9-b972-6bdaf87fc0f9
#UK #Huawei #Goodix #Patent